HK Stock Market Move | HENLIUS (02696) rose more than 4% in the afternoon recently. Hans Pharma's bridging trial for first-line treatment of small cell lung cancer in Japan has completed enrollment.

date
14:00 18/05/2026
avatar
GMT Eight
Fosun Pharma (02696) rose more than 4% in the afternoon, up 3.19% at the time of writing, closing at HK$69.65, with a turnover of HK$372.52 million.
HENLIUS (02696) rose more than 4% in the afternoon, with a rise of 3.19% at the time of writing, trading at HK$69.65, with a turnover of HK$37.252 million. In terms of news, recently, according to the official WeChat account of HENLIUS, the company announced that its innovative anti-PD-1 monoclonal antibody drug, Hetronifly (Sulituzumab, European trade name: Hetronifly), has successfully completed all subject enrollment in the bridging trial (NCT06812260) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in Japan. This bridging trial aims to evaluate the efficacy and safety of Hetronifly in combination with chemotherapy as a first-line treatment for ES-SCLC in Japanese patients, led by Professor Takayasu Kurata of Kansai Medical University Affiliated Hospital. The results of the NCT06812260 trial and the ASTRUM-005 study, which supports the approval of ES-SCLC in China and Europe, will together constitute key clinical data supporting the application for registration of Hetronifly in the Japanese market. The company plans to submit a listing application in collaboration with its Japanese partner WMC during its fiscal year 2026.